ASCO analysis: market access challenges in Europe for PD-1/PD-L1 targe…

19/06/2013

Christine Henry and Richard Wagner

Christine Henry and Richard Wagner of Kantar Health offer their opinions of the market access landscape for oncology in Europe following the recent 2013 ASCO annual meeting.Therapies that target the...

Addressing the challenge of cancer trial accrual

18/06/2013

Edwin Watson

Edwin Watson highlights the challenge of cancer trial accrual in our oncology themed month, and questions how we can encourage physicians to refer more patients to oncology clinical trials. The Current...

Sanofi Oncology pipeline update 2013

18/06/2013

Dr Tal Zaks

pharmaphorum's Hannah Blake catches up with Dr Tal Zaks from Sanofi Oncology to see where the global pharma company's oncology pipeline is heading, the unique partnerships that have helped Sanofi...

The changing face of oncology market access

17/06/2013

Cathy Wright

Cathy Wright of Succinct Healthcare Communications explores the changing face of oncology market access.There's no doubt that the NHS in England is going through a period of unprecedented change, and...

GSK receives offer for thrombosis brands

18/06/2013

Hannah Blake

GSK has received an offer from South African pharma company, Aspen, and it's wholly owned subsidiary, Aspen Global Incorporated, for its thrombosis brands and Notre-Dame de Bondeville (NDB) manufacturing site...

Lilly assumes development rights to potential type 2 diabetes drug

18/06/2013

Hannah Blake

Eli Lilly and Company has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate, TT-401, from Canada's Transition Therapeutics, who will receive a...

J&J announces $1bn deal to acquire Aragon Pharma

17/06/2013

Hannah Blake

Johnson & Johnson is to acquire cancer-focused company, Aragon Pharmaceuticals, in a definitive agreement worth up to US $1 billion.Aragon is a discovery and development company focused on drugs to...

Roche’s Avastin approved to treat aggressive brain cancer in Japan

17/06/2013

Hannah Blake

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Roche's Avastin for the treatment of rare disease, malignant glioma, in Japan. Avastin (bevacizumab) has also been approved for...

Perspectives on personalised healthcare …

Executive perspectives: Bruno Strigini

Doctors hold the key to understanding pa…

Carly Brown

Pharma is recognising the increasing importance of the patient voice in providing feedback on how medicines are utilised in a real-world setting and the impact they are having on outcomes....

Outcomes shape the new payer networks fo…

Marcelo Fantoni

The definition of the payer and the way in which healthcare spending decisions are made is changing, as complex networks of payers and clinicians become the new stakeholders with which...

Publishing white papers on pharmaphorum

Paul Tunnah

As a new feature on pharmaphorum, we unveil pharmaceutical industry white papers as part of our media section. Download this one page document to understand how to publish your deep...